

Application Serial No. 09/701,500

- 2 -

Dated June 23, 2004

**AMENDMENTS TO THE CLAIMS**

Claim 1 (currently amended). An article of manufacture comprising packaging material and a pharmaceutical composition contained within said packaging material, wherein said pharmaceutical composition is capable of stimulating angiogenesis in a tissue, wherein said packaging material comprises a label which indicates that said pharmaceutical composition can be directly administered to a tissue to stimulate angiogenesis in said tissue, and wherein said pharmaceutical composition comprises a nucleic acid having a nucleotide sequence capable of expressing an active human Src protein, and wherein the pharmaceutical composition contains a pharmaceutically acceptable carrier or excipient and an amount of said nucleic acid sufficient to deliver at least 0.1 grams of human Src protein per 100 grams of pharmaceutical composition.

Claims 2 and 3 (cancelled).

Claim 4 (previously presented). The article of manufacture of claim 1 wherein said tissue has poor circulation.

Claims 5-13 (canceled).

Claim 14 (original): The article of manufacture of claim 1 wherein said pharmaceutical composition further comprises a liposome.

Claim 15 (original): The article of manufacture of claim 1 wherein said pharmaceutical composition comprises a viral expression vector capable of expressing said nucleotide sequence.

Claim 16 (original): The article of manufacture of claim 1 wherein said pharmaceutical composition comprises an non-viral expression vector capable of expressing said nucleotide sequence.

Claims 17-32 (canceled).

Claim 33 (currently amended): A pharmaceutical composition for stimulating angiogenesis in a target mammalian tissue comprising a viral gene transfer vector containing a nucleic acid and a pharmaceutically acceptable carrier or excipient; said nucleic acid having a nucleic acid segment encoding for an active src protein having the amino acid residue sequence

Application Serial No. 09/701,500

- 3 -

Dated June 23, 2004

of SEQ ID NO: 5, wherein the pharmaceutical composition contains an amount of said nucleic acid sufficient to deliver at least 0.1 grams of the active src protein per 100 grams of pharmaceutical composition.

Claim 34 (currently amended): A pharmaceutical composition for stimulating angiogenesis in a target mammalian tissue comprising a non-viral gene transfer vector containing a nucleic acid and pharmaceutically acceptable carrier or excipient; said nucleic acid having a nucleic acid segment encoding for an active src protein having the amino acid residue sequence of SEQ ID NO: 5, wherein the pharmaceutical composition contains an amount of said nucleic acid sufficient to deliver at least 0.1 grams of the active src protein per 100 grams of pharmaceutical composition.

Claims 35-38 (canceled).